The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer

Genetic changes of non-small cell lung cancer under neoadjuvant therapy

(2016) Arne Warth et al.   Oncotarget

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

(2015) S. M. Reddy et al.   INVESTIGATIONAL NEW DRUGS

A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies

(2015) Matthew A. Gubens et al.   LUNG CANCER

The cellular growth rate controls overall mRNA turnover, and modulates either transcription or degradation rates of particular gene regulons

(2015) José García-Martínez et al.   NUCLEIC ACIDS RESEARCH

Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties

(2015) Ying-Jhen Su et al.   Oncotarget

Association between epithelial-mesenchymal transition and cancer stemness and their effect on the prognosis of lung adenocarcinoma

(2015) Terumasa Sowa et al.   Cancer Medicine

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†

(2014) I. A. McNeish et al.   ANNALS OF ONCOLOGY

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer

(2014) Makoto Sonobe et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer

(2014) T. Yoshida et al.   CLINICAL CANCER RESEARCH

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

(2014) Julian R. Molina et al.   LUNG CANCER

An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition

(2014) Laetitia Seguin et al.   NATURE CELL BIOLOGY

Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin  1/Src/Akt-Driven Bypass Signaling

(2013) R. Kanda et al.   CANCER RESEARCH

A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium

(2013) Scott A. Laurie et al.   Clinical Lung Cancer

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

(2013) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference

(2013) Megan R. Ansbro et al.   PLoS One

Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistancein vitroandin vivo

(2012) Ke-Jun Liu et al.   INTERNATIONAL JOURNAL OF CANCER

Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation

(2011) Carlos Mas-Moruno et al.   Anti-Cancer Agents in Medicinal Chemistry

Src family kinases and paclitaxel sensitivity

(2011) Xiao-Feng Le et al.   CANCER BIOLOGY & THERAPY

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

(2010) J. Baselga et al.   CLINICAL CANCER RESEARCH

Src Inhibitors in Lung Cancer: Current Status and Future Directions

(2010) Sacha I. Rothschild et al.   Clinical Lung Cancer

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation

(2010) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

mRNA turnover rate limits siRNA and microRNA efficacy

(2010) Erik Larsson et al.   Molecular Systems Biology

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

(2009) C Hegedűs et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression

(2009) Jay S Desgrosellier et al.   NATURE MEDICINE

Src kinases as therapeutic targets for cancer

(2009) Lori C. Kim et al.   Nature Reviews Clinical Oncology

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers

(2008) Hisao Asamura et al.   Journal of Thoracic Oncology

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?

(2008) Pascal Sève et al.   LANCET ONCOLOGY